Table 2.
Phase | Clinical Trial | Treatment | ClinicalTrials.gov Identifier |
---|---|---|---|
Phase 1/2 | CYP17 Lyase and Androgen Receptor Inhibitor treatment with Seviteronel | Seviteronel | NCT02580448 |
Phase 1 Phase 2 |
A phase I/II, single arm, non-randomized study of Ribociclib (LEE011), a CDK 4/6 inhibitor, in combination with Bicalutamide, an androgen receptor (AR) inhibitor | Ribociclib Bicalutamide | NCT03090165 |
Phase 1 Phase 2 |
A phase Ib/II trial of Taselisib (GDC-0032), a PI3K inhibitor, in combination with Enzalutamide in patient with AR+veTNBC | Enzalutamide Taselisib | NCT02457910 |
Phase 2 | A phase 2 open-label study to evaluate the efficacy and safety of VT-464, previous treatment with Enzalutamide | VT-464 | NCT02130700 |